Intra-Cellular Therapies develops innovative drugs for neuropsychiatric and neurologic diseases in the US, including CAPLYTA for schizophrenia treatment in adults. Its other flagship drug, lumateperone, is in Phase III clinical trials for bipolar depression and autism spectrum disorder treatment, among other neuropsychiatric indications. The company is also developing Lenrispodun, ITI-1284-ODT-SL and ITI-333 for various health conditions like Parkinson's disease, heart failure, substance use disorders, pain, and psychiatric comorbidities.